Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: An effective, more convenient alternative to weekly administration?

Oncologist

Volumn 13, Issue 2, 2008, Pages 113-119

  Tabernero, Josep ^a   Pfeiffer, Per ^b   Cervantes, Andrés ^c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cetuximab; Colorectal cancer; Every two weeks; Pharmacodynamics; Pharmacokinetics; Weekly

Indexed keywords

CETUXIMAB; CETUXIMAB PLUS IRINOTECAN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG;

ACNE LIKE SKIN RASH; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; METASTASIS; MONOTHERAPY; NEUTROPENIA; PHARMACODYNAMICS; PRIORITY JOURNAL; SKIN TOXICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; HUMANS; TIME FACTORS;

EID: 40349087139     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0201     Document Type: Article

References (35)